Atara Biotherapeutics (NASDAQ:ATRA) Shares Cross Below Fifty Day Moving Average – Time to Sell?

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares crossed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $10.71 and traded as low as $7.35. Atara Biotherapeutics shares last traded at $7.52, with a volume of 77,487 shares.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Rodman & Renshaw initiated coverage on shares of Atara Biotherapeutics in a report on Friday, December 20th. They issued a “buy” rating and a $25.00 target price on the stock. RODMAN&RENSHAW lowered Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 21st. Canaccord Genuity Group cut their target price on Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, January 17th. TD Cowen upgraded Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th. Finally, HC Wainwright reissued a “neutral” rating on shares of Atara Biotherapeutics in a research note on Tuesday, January 28th. One analyst has rated the stock with a sell rating, three have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.75.

Atara Biotherapeutics Price Performance

The firm has a fifty day simple moving average of $10.71 and a 200-day simple moving average of $9.75. The firm has a market cap of $43.32 million, a P/E ratio of -0.29 and a beta of 0.46.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC grew its holdings in shares of Atara Biotherapeutics by 9.5% during the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after buying an additional 4,043 shares during the last quarter. State Street Corp lifted its position in Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after acquiring an additional 7,680 shares in the last quarter. FMR LLC boosted its stake in Atara Biotherapeutics by 41.7% during the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 7,381 shares during the last quarter. Vestal Point Capital LP increased its holdings in Atara Biotherapeutics by 11.3% during the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock worth $1,014,000 after purchasing an additional 12,677 shares in the last quarter. Finally, Northern Trust Corp purchased a new stake in shares of Atara Biotherapeutics in the fourth quarter worth approximately $149,000. Institutional investors and hedge funds own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.